REFERENCES
- Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant. 2005;5(1):50–57.
- Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358(9292):1511–1513.
- El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr. 2007;150(4):376–382.
- Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639–2642.
- Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, Rituximab therapy for childhood Evans syndrome. Haematologica. 2007;92(12):1691–1694.
- Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis. 2003;36(3):e47–e49.
- Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000;96(3):1184–1186.
- Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev. 2002;16(1):61–64.
- Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003;143(5):662–665.
- Wedgwood RJ, Ochs HD, Davis SD. The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174. Birth Defects Orig Artic Ser. 1975;11(1):331–338.
- Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest. 1971;50(12):2559–2568.
- Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood. 1998;92(7):2421–2434.
- Fudenberg H, Good RA, Goodman HC, Hitzig W, Kunkel HG, Roitt IM, Primary immunodeficiencies. Report of a World Health Organization Committee. Pediatrics. 1971;47(5):927–946.
- Rao, VK, Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood and Cancer. 2009;52:847–852.
- Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. British Journal of Haematology. 2009;146:120–122.